- To assess other measures of anti-tumor activity of the combination of pembrolizumab and cabozantinib in subjects with locally advanced or metastatic renal cell carcinoma that has progressed after treatment with at least one prior VEGF-targeted therapy, or for whom VEGF-targeted therapy has proven to be intolerable, or is considered inappropriate.